The first phase of Honkai Star Rail 3.3 is nearing its end, and Trailblazers are eagerly waiting for the upcoming 5-star unit, Cipher. Your login session has expired.

Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase kinase‐3 beta (GSK-3β) drug showed a three-month survival increase in a ...

In a big leap for Mumbai’s public transport, Metro Line 3's second phase—connecting Bandra-Kurla Complex (BKC) to Acharya Atre Chowk in Worli—officially began operations on Saturday ...

Company’s PALISADE-4 Phase 3 trial now expected to read out in the first half of 2026. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical ...

In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced ...

Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.

Yvonne Odoley Sowah, who served on the GIIF Board from 2017 to 2021, explicitly declared in her statement dated May 28, 2025, that during her time, former CEO Solomon Asamoah "did not submit any ...

We report the interim analysis of efficacy and safety outcomes of Padeliporfin VTP for treatment of LG UTUC in ENLIGHTED, a Phase 3 trial (NCT04620239). Methods: This is an open-label phase 3 study ...

The aim of this phase 3 study is to confirm the efficacy and safety of relacorilant + nab-paclitaxel in a larger population. Methods: ROSELLA (NCT05257408) is a randomized, controlled, open-label, ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.